Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer

Abstract

Purpose: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH (HGNC:3700). This paper quantitatively weights the phenotypic context (PP4/PS4) of such very rare variants in FH. Methods: We collated clinical diagnostic testing data on germline FH variants from 387 individuals with HLRCC and 1,780 individuals with renal cancer, and compared the frequency of 'very rare' variants in each phenotypic cohort against 562,295 population controls. We generated pan-gene very rare variant likelihood ratios (PG-VRV-LRs), and domain-specific likelihood ratios for missense variants (DS-VRMV-LR) using spatial clustering analysis, and log likelihood ratios (LLRs) as applicable within the updated ACMG/AMP Variant Classification Framework. Results: For HLRCC, the PG-VRV-LR was estimated to be 2,669.4 (95% CI: 1,843.4-3,881.2, LLR 10.77) for truncating variants and 214.7 (185.0-246.9, LLR 7.33) for missense variants. For renal cancer, the PG-VRV-LR was 95.5 (48.9-183.0, LLR 6.23) for truncating variants and 5.8 (3.5-9.3, LLR 2.39) for missense variants. Clustering analysis in HLRCC cases revealed three 'hotspot' regions wherein the DS-VRMV-LR increased to 1226.9. Conclusion: These data provide quantitative measures for very rare missense and truncating variants in FH, which reflect the differing phenotypic specificity of HLRCC and renal cancer, and may be applicable in clinical variant classification.

Publication DOI: https://doi.org/10.1016/j.gim.2025.101565
Divisions: College of Health & Life Sciences > Aston Medical School
College of Health & Life Sciences
Aston University (General)
Funding Information: A full list of CanVIG-UK consortium members and their affiliations appears in the Supplemental Material. The Article Publishing Charge (APC) for this article was paid by the Institute of Cancer Research. This work was made available as a pre-print on medR
Additional Information: Copyright © 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).
Uncontrolled Keywords: variant interpretation,HLRCC,germline,renal cancer,FH
Publication ISSN: 1530-0366
Data Access Statement: All data generated or analysed during this study are either included in this published article and its supplementary information files, are available from the corresponding author on request, or are publicly available at the references and URLs provided. This research has been conducted using the UK Biobank Resource under Application Number 76689<br/>(https://www.ukbiobank.ac.uk/).
Last Modified: 07 Oct 2025 12:13
Date Deposited: 24 Sep 2025 13:54
Full Text Link:
Related URLs: https://www.sci ... 098360025002126 (Publisher URL)
PURE Output Type: Article
Published Date: 2025-11-01
Published Online Date: 2025-09-04
Accepted Date: 2025-08-14
Submitted Date: 2024-11-28
Authors: Allen, Sophie
Rowlands, Charlie F.
Butler, Samantha
Durkie, Miranda
Horton, Carrie
Pesaran, Tina
Richardson, Marcy
Robinson, Rachel
Garrett, Alice
Burghel, George J.
Callaway, Alison
Field, Joanne
Frugtniet, Bethan
Palmer-Smith, Sheila
Grant, Jonathan
Pagan, Judith
McDevitt, Trudi
Snape, Katie
Andreou, Avgi
Maher, Eamonn R.
Hanson, Helen
McVeigh, Terri
Turnbull, Clare

Download

[img]

Version: Published Version

License: Creative Commons Attribution


Export / Share Citation


Statistics

Additional statistics for this record